Literature DB >> 8605353

Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage.

R Scuderi1, K A Palucka, K Pokrovskaja, M Björkholm, K G Wiman, P Pisa.   

Abstract

Using Western blot analysis, we examined cyclin E and cyclin A protein levels in 19 patients with acute lymphoblastic leukemia ([ALL] 15 B-ALL and four T-ALL). Whereas normal, nonproliferating peripheral blood mononuclear cells (PBMCs) expressed low levels of the 50-kD cyclin E, ALL blasts in the peripheral blood, although showing low-level or no proliferation as judged by FACS/cell-cycle analysis and cyclin A protein levels, expressed high levels of cyclin E, with a mean value similar to that of the proliferating Burkitt's lymphoma cell line, Akata. The accumulation of a protein shown to shorten the G1 phase of the cell cycle, cyclin E, in growth-delayed leukemic blasts may reflect the malignant status of these cells. Before treatment, B-ALL cells expressed predominantly the 50-kD cyclin E. T-ALL samples displayed the 50-kD cyclin E protein and a smaller, approximately 43-kD cyclin E species. In paired B-ALL samples taken before treatment and at relapse, we found a significant overexpression of the 50-kD protein in relapsed samples (P < .006), plus the presence of up to four additional smaller-molecular-weight species of cyclin E, illustrating clear diagnosis versus relapse differences. Cyclin E expression in ALL blasts may correlate to the relative malignant status of the cells, with higher protein levels reflecting a more advanced stage of the disease and a greater potential to proliferate under permissive conditions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8605353

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Novel splice variants of cyclin E with altered substrate specificity.

Authors:  D C Porter; K Keyomarsi
Journal:  Nucleic Acids Res       Date:  2000-12-01       Impact factor: 16.971

Review 2.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.

Authors:  Katrien Vermeulen; Dirk R Van Bockstaele; Zwi N Berneman
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

3.  NFAT1 transcription factor regulates cell cycle progression and cyclin E expression in B lymphocytes.

Authors:  Leonardo K Teixeira; Nina Carrossini; Cristiane Sécca; José E Kroll; Déborah C DaCunha; Douglas V Faget; Lilian D S Carvalho; Sandro J de Souza; João P B Viola
Journal:  Cell Cycle       Date:  2016-07-11       Impact factor: 4.534

4.  Cul3 regulates cyclin E1 protein abundance via a degron located within the N-terminal region of cyclin E.

Authors:  Brittney Davidge; Katia Graziella de Oliveira Rebola; Larry N Agbor; Curt D Sigmund; Jeffrey D Singer
Journal:  J Cell Sci       Date:  2019-11-06       Impact factor: 5.285

5.  Nitric oxide induces apoptosis in NALM-6, a leukaemia cell line with low cyclin E protein levels.

Authors:  M Mozart; R Scuderi; F Celsing; M Aguilar-Santelises
Journal:  Cell Prolif       Date:  2001-12       Impact factor: 6.831

6.  Expression of cyclin D1 and cyclin E in urothelial bladder carcinoma detected in tissue chips using a quantum dot immunofluorescence technique.

Authors:  Guang Shan; Tian Tang
Journal:  Oncol Lett       Date:  2015-06-30       Impact factor: 2.967

7.  Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1.

Authors:  C Liao; X Y Wang; H Q Wei; S Q Li; T Merghoub; P P Pandolfi; D J Wolgemuth
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

8.  Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL.

Authors:  Benedetta Accordi; Virginia Espina; Marco Giordan; Amy VanMeter; Gloria Milani; Luisa Galla; Maria Ruzzene; Manuela Sciro; Luca Trentin; Ruggero De Maria; Geertruy te Kronnie; Emanuel Petricoin; Lance Liotta; Giuseppe Basso
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

9.  Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia.

Authors:  Hong He; Yukio Kondo; Ken Ishiyama; Gheath Alatrash; Sijie Lu; Kathryn Cox; Na Qiao; Karen Clise-Dwyer; Lisa St John; Pariya Sukhumalchandra; Qing Ma; Jeffrey J Molldrem
Journal:  Leukemia       Date:  2020-01-06       Impact factor: 11.528

10.  Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53.

Authors:  V C Padmakumar; Eiman Aleem; Cyril Berthet; Mary Beth Hilton; Philipp Kaldis
Journal:  Mol Cell Biol       Date:  2009-03-23       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.